Contact Us
+1877- DYNAMILL (3962 6455)
Our Location
16W285 83rd St. STE D-1 Burr Ridge, IL 60527
info@dynamillcro.com
Social Network
Close
Bringing a medical device, diagnostic technology, or in vitro diagnostic (IVD) product to market requires more than a strong innovation. Sponsors need a clear regulatory pathway, a defensible clinical evidence strategy, submission-ready documentation, and a study plan designed around the evidence FDA will need to review.
Dynamill CRO provides medical device regulatory consulting, IVD regulatory consulting, FDA submission support, and clinical research services for medical device and diagnostic companies. We help sponsors connect regulatory strategy directly to clinical study design and execution so development programs are not only scientifically sound and operationally feasible, but also aligned with the intended submission pathway.
Whether you are preparing for an FDA Pre-Submission interaction, 510(k), De Novo, PMA, IDE, eSTAR submission, or an IVD clinical performance program, Dynamill helps build the regulatory and clinical evidence roadmap needed to move forward with confidence.
Regulatory planning should not begin after a clinical study is complete. Early decisions around intended use, indications, target population, comparator selection, endpoints, specimen strategy, site capability, data quality, and documentation can materially affect the strength and efficiency of a future submission.
Dynamill provides medical device regulatory strategy and FDA medical device consulting to help sponsors clarify the regulatory objective early, identify likely evidence needs, and translate those needs into an executable development plan. This is particularly important for IVD and diagnostic programs, where specimen flow, reference methods, laboratory processes, comparator testing, analytical performance, clinical performance, and data traceability may all affect the evidence package.
Our approach bridges regulatory intent and clinical execution. The goal is to reduce the risk of running a study that succeeds operationally but leaves evidence gaps when the sponsor reaches an FDA interaction or submission milestone.
Dynamill provides FDA submission support for medical devices and IVDs by helping sponsors organize development activities around the appropriate regulatory pathway and evidence expectations. Depending on the product, risk classification, intended use, claims, and predicate or comparator landscape, sponsors may need very different submission strategies.
Support may include regulatory pathway assessment, evidence gap review, submission planning, study design input, clinical investigation planning, document readiness, and coordination across regulatory, clinical, scientific, quality, data, and operational stakeholders. For diagnostic and IVD companies, we also help align specimen type, target population, comparator method, clinical workflow, performance endpoints, and study documentation with the intended submission strategy.
For products with a potential predicate, Dynamill provides 510(k) submission support and 510(k) consulting focused on aligning intended use, device performance, clinical evidence, and documentation with the submission strategy. We help sponsors assess whether additional clinical evidence may be needed and, when it is, how to generate that evidence efficiently.
For novel devices without a suitable predicate, Dynamill provides De Novo submission support, including planning around risk classification, benefit-risk evidence, clinical study design, performance data, and documentation needs. For higher-risk devices, our PMA submission support focuses on clinical evidence planning, study documentation, safety oversight, data quality, and submission readiness.
Dynamill can also support IDE planning for investigational devices and eSTAR submission preparation by helping teams organize evidence, documentation, and cross-functional inputs around the selected pathway. The objective is to build submission readiness throughout development rather than assemble it only at the end.
Early FDA interaction can be valuable when sponsors need feedback on regulatory pathway, study design, clinical evidence expectations, comparator strategy, endpoints, testing plans, or other development questions. Dynamill supports FDA Pre-Submission and Q-Submission planning by helping sponsors define the questions that matter most, identify supporting evidence, organize briefing materials, and prepare cross-functional teams for productive agency interaction.For sponsors preparing clinical studies, a well-planned Pre-Sub can help align the study strategy with the intended future submission.
IVD products have distinct development and regulatory challenges. Clinical evidence often depends on specimen quality, collection methods, laboratory workflow, comparator or reference methods, sample handling, disease prevalence, site capability, and complete data traceability. Dynamill provides IVD regulatory consulting and FDA IVD submission support by connecting the intended use of the test with the clinical and analytical evidence needed to support that use. We help sponsors plan around target population, disease setting, specimen type, sample logistics, reference methods, study feasibility, performance endpoints, and documentation readiness.
A regulatory strategy is only as strong as the evidence generated to support it. Dynamill combines regulatory consulting with medical device CRO, IVD CRO, and diagnostic CRO capabilities to help sponsors translate regulatory objectives into executable clinical studies.
Our clinical evidence strategy support may include protocol and study design, endpoint planning, inclusion and exclusion criteria, comparator strategy, site selection, feasibility, enrollment planning, data collection, monitoring strategy, biostatistical planning, and documentation standards. For IVD clinical trials and IVD clinical performance studies, this may also include specimen collection planning, laboratory workflow mapping, sample logistics, reference testing, discordant result management, and quality control procedures.
This integrated approach is designed to reduce avoidable protocol amendments, evidence gaps, unclear results, incomplete documentation, and late-stage rework. It also gives sponsors a single partner that can connect regulatory strategy with the practical realities of clinical trial execution.
Diagnostic technologies require careful alignment between scientific performance, clinical performance, intended use, and the population in which the product will be used. A test may perform well technically but still create regulatory challenges if the study population, comparator, endpoints, specimen mix, or data structure do not support the proposed claims.
Dynamill supports diagnostic clinical validation and clinical performance programs for molecular diagnostics, companion diagnostics, and other IVD technologies. Our team helps sponsors assess the strength of the planned evidence package, identify gaps early, and build an operational strategy that supports both study execution and future regulatory milestones.
With the FDA Quality Management System Regulation (QMSR) now in effect, medical device and IVD sponsors should consider quality systems, design controls, documentation, risk management, and lifecycle evidence as part of the broader development strategy. Quality documentation should not be treated as disconnected from clinical development and submission planning.
Dynamill helps sponsors consider how regulatory strategy, clinical evidence, risk documentation, study records, monitoring outputs, and quality processes fit together across the development lifecycle. The goal is a consistent, traceable evidence package that is easier to defend at regulatory milestones.
Dynamill can support medical device, diagnostic, and IVD sponsors across the following areas:
Dynamill is built around the needs of diagnostic, IVD, and medical device development programs. Our model combines regulatory awareness with practical clinical operations experience, helping sponsors design studies that are feasible, well documented, and aligned with the evidence needed for regulatory review.
Medical device and diagnostic studies often involve complex workflows, site variability, laboratory coordination, specimen handling, comparator methods, specialized endpoints, and challenging enrollment dynamics. By connecting regulatory strategy to clinical execution from the outset, Dynamill helps sponsors address those complexities earlier and build a stronger, more coherent evidence package.
Medical device regulatory consulting can include regulatory pathway assessment, FDA interaction planning, submission strategy, evidence gap review, clinical study planning, documentation readiness, and cross-functional coordination. The objective is to align development activities with the evidence and documentation expected for the intended regulatory pathway.
Yes. Dynamill supports diagnostic and IVD sponsors with regulatory strategy as well as clinical study planning and execution. This may include IVD clinical performance studies, specimen and comparator strategy, site feasibility, data-quality planning, and submission-readiness support.
Yes. Dynamill supports planning and evidence readiness for 510(k), De Novo, PMA, and IDE-related pathways, as well as eSTAR submission preparation. The specific scope depends on the device, intended use, evidence base, development stage, and submission strategy.
Yes. Dynamill can help sponsors define key FDA questions, assess evidence gaps, organize briefing materials, prepare teams for agency interaction, and translate feedback into study and submission actions.
Planning should begin before the clinical study starts. Early alignment helps ensure that the population, endpoints, comparator, specimen plan, and data collection support the intended regulatory pathway and claims.
Combining regulatory strategy with clinical execution reduces handoffs and helps keep protocol design, sites, enrollment, monitoring, data, specimens, and documentation aligned with the regulatory objective, reducing late-stage evidence gaps and avoidable rework.
Contact Us
+1877- DYNAMILL (3962 6455)
Our Location
16W285 83rd St. STE D-1 Burr Ridge, IL 60527
info@dynamillcro.com
Social Network